Status:
COMPLETED
Management of Irritable Bowel Syndrome in Primary Care (MIBS Trial)
Lead Sponsor:
Hazel Everitt
Collaborating Sponsors:
National Institute for Health Research, United Kingdom
Conditions:
Irritable Bowel Syndrome
Eligibility:
All Genders
16-60 years
Phase:
PHASE4
Brief Summary
Aims: 1. To pilot an randomized, controlled trial (RCT) to assess the effectiveness of the commonly prescribed medications in UK general practice for IBS: mebeverine (anti-spasmodic) and methylcellul...
Detailed Description
Background: Irritable bowel syndrome (IBS) affects 10-22% of the United Kingdom (UK) population, with National Health Service (NHS) costs over £200 million a year. Abdominal pain, bloating and altere...
Eligibility Criteria
Inclusion
- Patients aged 16 to 60 years with symptoms of irritable bowel syndrome that fulfill the Rome III criteria
Exclusion
- Atypical symptoms (unexplained weight loss, rectal bleeding)
- Diagnosis of inflammatory bowel disease, coeliac disease or peptic ulcer disease
- Pregnant or breast feeding
- Currently taking or allergy to mebeverine or methylcellulose
Key Trial Info
Start Date :
April 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2011
Estimated Enrollment :
135 Patients enrolled
Trial Details
Trial ID
NCT00934973
Start Date
April 1 2010
End Date
October 1 2011
Last Update
April 30 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Southampton
Southampton, Hampshire, United Kingdom, SO17 1JB